Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis

Cilostazol has promise as an alternative to aspirin for secondary stroke prevention given its vasodilatory and anti-inflammatory properties in addition to platelet aggregation inhibition. We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol compared to aspirin for stroke prevention in patients with previous stroke or transient ischemic attack (TIA).

Source: Journal of Stroke and Cerebrovascular Diseases - December 31, 2020 Category: Neurology Authors: Michelle P. Lin, James F. Meschia, Neethu Gopal, Kevin M. Barrett, Owen A. Ross, Nil üfer Ertekin-Taner, Thomas G. Brott Source Type: research